These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
393 related articles for article (PubMed ID: 37483515)
1. Insight into lipid-based nanoplatform-mediated drug and gene delivery in neuro-oncology and their clinical prospects. Hegde MM; Sandbhor P; J A; Gota V; Goda JS Front Oncol; 2023; 13():1168454. PubMed ID: 37483515 [TBL] [Abstract][Full Text] [Related]
2. Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies. Zhao X; Ye Y; Ge S; Sun P; Yu P Curr Top Med Chem; 2020; 20(30):2762-2776. PubMed ID: 32851962 [TBL] [Abstract][Full Text] [Related]
3. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies. Goel H; Kalra V; Verma SK; Dubey SK; Tiwary AK J Control Release; 2022 Jan; 341():782-811. PubMed ID: 34906605 [TBL] [Abstract][Full Text] [Related]
5. Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology. Foster JB; Alonso MM; Sayour E; Davidson TB; Persson ML; Dun MD; Kline C; Mueller S; Vitanza NA; van der Lugt J Neoplasia; 2023 Aug; 42():100909. PubMed ID: 37244226 [TBL] [Abstract][Full Text] [Related]
6. On the future development of optimally-sized lipid-insoluble systemic therapies for CNS solid tumors and other neuropathologies. Sarin H Recent Pat CNS Drug Discov; 2010 Nov; 5(3):239-52. PubMed ID: 20722627 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic nanoplatforms and delivery strategies for neurological disorders. Kang YJ; Cutler EG; Cho H Nano Converg; 2018 Nov; 5(1):35. PubMed ID: 30499047 [TBL] [Abstract][Full Text] [Related]
8. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders. Correia AC; Monteiro AR; Silva R; Moreira JN; Sousa Lobo JM; Silva AC Adv Drug Deliv Rev; 2022 Oct; 189():114485. PubMed ID: 35970274 [TBL] [Abstract][Full Text] [Related]
9. Nanoparticulate devices for brain drug delivery. Celia C; Cosco D; Paolino D; Fresta M Med Res Rev; 2011 Sep; 31(5):716-56. PubMed ID: 20162690 [TBL] [Abstract][Full Text] [Related]
10. The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors. Del Baldo G; Del Bufalo F; Pinacchio C; Carai A; Quintarelli C; De Angelis B; Merli P; Cacchione A; Locatelli F; Mastronuzzi A Front Immunol; 2023; 14():1142597. PubMed ID: 37025994 [TBL] [Abstract][Full Text] [Related]
11. Nanobiotechnology-based drug delivery in brain targeting. Dinda SC; Pattnaik G Curr Pharm Biotechnol; 2013; 14(15):1264-74. PubMed ID: 24910011 [TBL] [Abstract][Full Text] [Related]
12. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting. Agrawal M; Saraf S; Saraf S; Dubey SK; Puri A; Patel RJ; Ajazuddin ; Ravichandiran V; Murty US; Alexander A J Control Release; 2020 May; 321():372-415. PubMed ID: 32061621 [TBL] [Abstract][Full Text] [Related]
13. Application of Therapeutic Nanoplatforms as a Potential Candidate for the Treatment of CNS Disorders: Challenges and Possibilities. Sa P; Singh P; Dilnawaz F; Sahoo SK Curr Pharm Des; 2022; 28(33):2742-2757. PubMed ID: 35909283 [TBL] [Abstract][Full Text] [Related]
14. Nanoparticles as immunomodulators and translational agents in brain tumors. Grippin AJ; Dyson KA; Qdaisat S; McGuiness J; Wummer B; Mitchell DA; Mendez-Gomez HR; Sayour EJ J Neurooncol; 2021 Jan; 151(1):29-39. PubMed ID: 32757093 [TBL] [Abstract][Full Text] [Related]
15. TRAIL-modified, doxorubicin-embedded periodic mesoporous organosilica nanoparticles for targeted drug delivery and efficient antitumor immunotherapy. Feng X; Li F; Zhang L; Liu W; Wang X; Zhu R; Qiao ZA; Yu B; Yu X Acta Biomater; 2022 Apr; 143():392-405. PubMed ID: 35259519 [TBL] [Abstract][Full Text] [Related]
16. Nanomedicine-based immunotherapy for central nervous system disorders. Hanif S; Muhammad P; Chesworth R; Rehman FU; Qian RJ; Zheng M; Shi BY Acta Pharmacol Sin; 2020 Jul; 41(7):936-953. PubMed ID: 32467570 [TBL] [Abstract][Full Text] [Related]
17. Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors? Brioschi A; Zenga F; Zara GP; Gasco MR; Ducati A; Mauro A Neurol Res; 2007 Apr; 29(3):324-30. PubMed ID: 17509234 [TBL] [Abstract][Full Text] [Related]
18. Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We? Quintarelli C; Camera A; Ciccone R; Alessi I; Del Bufalo F; Carai A; Del Baldo G; Mastronuzzi A; De Angelis B Front Immunol; 2021; 12():634031. PubMed ID: 34163465 [TBL] [Abstract][Full Text] [Related]
19. Nanoparticulate systems for drug delivery and targeting to the central nervous system. Craparo EF; Bondì ML; Pitarresi G; Cavallaro G CNS Neurosci Ther; 2011 Dec; 17(6):670-7. PubMed ID: 20950327 [TBL] [Abstract][Full Text] [Related]
20. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches. Juratli TA; Schackert G; Krex D Pharmacol Ther; 2013 Sep; 139(3):341-58. PubMed ID: 23694764 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]